JP2024529067A5 - - Google Patents
Info
- Publication number
- JP2024529067A5 JP2024529067A5 JP2024507164A JP2024507164A JP2024529067A5 JP 2024529067 A5 JP2024529067 A5 JP 2024529067A5 JP 2024507164 A JP2024507164 A JP 2024507164A JP 2024507164 A JP2024507164 A JP 2024507164A JP 2024529067 A5 JP2024529067 A5 JP 2024529067A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate according
- optionally substituted
- halogens
- conjugate
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229628P | 2021-08-05 | 2021-08-05 | |
| US63/229,628 | 2021-08-05 | ||
| PCT/US2022/039517 WO2023014938A1 (en) | 2021-08-05 | 2022-08-05 | 1'-alkyl modified ribose derivatives and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024529067A JP2024529067A (ja) | 2024-08-01 |
| JP2024529067A5 true JP2024529067A5 (https=) | 2025-08-08 |
| JP7842850B2 JP7842850B2 (ja) | 2026-04-08 |
Family
ID=83049985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507164A Active JP7842850B2 (ja) | 2021-08-05 | 2022-08-05 | １’－アルキル修飾リボース誘導体及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12465647B2 (https=) |
| EP (1) | EP4380946A1 (https=) |
| JP (1) | JP7842850B2 (https=) |
| KR (1) | KR20240070519A (https=) |
| CN (1) | CN117980315A (https=) |
| AU (1) | AU2022324471A1 (https=) |
| CA (1) | CA3227661A1 (https=) |
| IL (1) | IL310547A (https=) |
| MX (1) | MX2024001581A (https=) |
| WO (1) | WO2023014938A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4413015A1 (en) * | 2021-10-05 | 2024-08-14 | Sanegene Bio USA Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
| KR20250088573A (ko) * | 2022-10-14 | 2025-06-17 | 사네진 바이오 유에스에이 인크. | C3을 표적화하는 소형 간섭 rna 및 그의 용도 |
| MX2025013094A (es) * | 2023-05-03 | 2026-02-03 | Sanegene Bio Usa Inc | Conjugados basados en lipidos para la administracion sistemica en el sistema nervioso central, el sistema nervioso periferico y ocular |
| US20250064939A1 (en) * | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| CN116854754B (zh) | 2023-09-01 | 2023-12-12 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
| CN121263426A (zh) * | 2024-05-09 | 2026-01-02 | 石药集团中奇制药技术（石家庄）有限公司 | GalNAc衍生物及其寡聚核苷酸缀合物 |
| WO2025256544A1 (zh) * | 2024-06-11 | 2025-12-18 | 福建盛迪医药有限公司 | 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法 |
| US20250382616A1 (en) * | 2024-06-18 | 2025-12-18 | Sanegene Bio Usa Inc. | Small interfering rna targeting cfb and uses thereof |
| WO2026017140A2 (en) | 2024-07-18 | 2026-01-22 | Sanegene Bio Usa Inc. | Small interfering rna targeting fxi and uses thereof |
| WO2026030554A1 (en) * | 2024-07-31 | 2026-02-05 | Sanegene Bio Usa Inc. | Saccharide-based conjugates for rna delivery and therapy |
| CN118638166B (zh) | 2024-08-15 | 2024-12-17 | 北京悦康科创医药科技股份有限公司 | 含有三氮唑结构的GalNAc化合物及其寡核苷酸缀合物 |
| WO2026041067A2 (en) | 2024-08-20 | 2026-02-26 | Sanegene Bio Usa Inc. | Small interfering rna targeting myostatin (mstn) and uses thereof |
| WO2026046411A1 (en) | 2024-09-02 | 2026-03-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting plasminogen (plg) and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US154A (en) | 1837-03-30 | Improvement in machines for cutting the threads of wood-screws | ||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| AU637800B2 (en) | 1989-08-31 | 1993-06-10 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US6365730B1 (en) | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| US6172208B1 (en) * | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| WO1996011266A2 (en) | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| ES2702942T3 (es) | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CA3131967A1 (en) | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
| CN107080847A (zh) * | 2011-06-24 | 2017-08-22 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
| US8577565B2 (en) | 2011-12-16 | 2013-11-05 | GM Global Technology Operations LLC | Limiting branch pressure to a solenoid valve in a fluid circuit |
| AU2013299717B2 (en) * | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| DK3569711T3 (da) * | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| MX2018015109A (es) | 2016-06-06 | 2019-04-22 | Arrowhead Pharmaceuticals Inc | Nucleotidos modificados con 5'-ciclo-fosfonato. |
| JP7249080B2 (ja) | 2016-08-23 | 2023-03-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| SG11202009877XA (en) * | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
-
2022
- 2022-08-05 US US17/881,935 patent/US12465647B2/en active Active
- 2022-08-05 AU AU2022324471A patent/AU2022324471A1/en active Pending
- 2022-08-05 CN CN202280061450.4A patent/CN117980315A/zh active Pending
- 2022-08-05 WO PCT/US2022/039517 patent/WO2023014938A1/en not_active Ceased
- 2022-08-05 MX MX2024001581A patent/MX2024001581A/es unknown
- 2022-08-05 KR KR1020247007393A patent/KR20240070519A/ko active Pending
- 2022-08-05 JP JP2024507164A patent/JP7842850B2/ja active Active
- 2022-08-05 CA CA3227661A patent/CA3227661A1/en active Pending
- 2022-08-05 EP EP22758376.2A patent/EP4380946A1/en active Pending
- 2022-08-05 IL IL310547A patent/IL310547A/en unknown
-
2025
- 2025-07-28 US US19/282,328 patent/US20260021188A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529067A5 (https=) | ||
| JP2025041652A5 (https=) | ||
| JP2025508785A5 (https=) | ||
| JP2024534502A5 (https=) | ||
| JP2022535911A5 (https=) | ||
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| JP2022505234A5 (https=) | ||
| JP2023164871A5 (https=) | ||
| JP2020522265A5 (https=) | ||
| JP2024040167A5 (https=) | ||
| JP2022547716A5 (https=) | ||
| JP2024540101A5 (https=) | ||
| JP2021502120A5 (https=) | ||
| CN106188192B (zh) | 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途 | |
| JP2022534702A5 (https=) | ||
| JP2022501408A5 (https=) | ||
| JP2024540108A5 (https=) | ||
| JP2022527569A5 (https=) | ||
| JP2001527052A5 (https=) | ||
| JP2022533722A5 (https=) | ||
| JP2021526017A5 (https=) | ||
| JP2021533800A5 (https=) | ||
| JP2024023349A5 (https=) | ||
| JP2022534069A5 (https=) | ||
| JP2015063538A (ja) | ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 |